Deutsche Bank AG Takes Position in DexCom, Inc. $DXCM

Deutsche Bank AG bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,435,559 shares of the medical device company’s stock, valued at approximately $164,035,000. Deutsche Bank AG owned approximately 0.65% of DexCom as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of DXCM. Geode Capital Management LLC raised its holdings in DexCom by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock valued at $727,842,000 after acquiring an additional 42,411 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of DexCom by 6.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock worth $530,897,000 after acquiring an additional 516,526 shares during the period. Norges Bank purchased a new stake in shares of DexCom during the fourth quarter worth about $483,356,000. Invesco Ltd. raised its stake in DexCom by 14.8% during the 4th quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock valued at $352,781,000 after purchasing an additional 686,228 shares during the period. Finally, CIBC Private Wealth Group LLC raised its stake in DexCom by 7.6% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock valued at $207,613,000 after purchasing an additional 220,313 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on DXCM shares. Robert W. Baird set a $105.00 price target on DexCom in a research note on Friday, July 31st. Piper Sandler reissued an “overweight” rating and issued a $95.00 target price (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Stifel Nicolaus set a $95.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Royal Bank Of Canada raised their target price on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $88.71.

Insider Buying and Selling at DexCom

In other news, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the sale, the insider directly owned 328,970 shares in the company, valued at $25,106,990.40. The trade was a 7.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the sale, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,035 shares of company stock valued at $5,446,673. Corporate insiders own 0.28% of the company’s stock.

DexCom Stock Up 0.3%

NASDAQ DXCM opened at $89.88 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The company has a market capitalization of $33.92 billion, a P/E ratio of 35.53, a P/E/G ratio of 1.51 and a beta of 1.41. DexCom, Inc. has a one year low of $54.11 and a one year high of $91.96. The stock has a 50 day moving average price of $76.85 and a 200-day moving average price of $70.67.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.48 earnings per share. As a group, equities analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.